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Objective. To estimate the early prevalence of various electrocardiographic (EKG) abnormalities in patients with
systemic lupus erythematosus (SLE) and to evaluate possible associations between repolarization changes (increased
corrected QT [QTc] and QT dispersion [QTd]) and clinical and laboratory variables, including the anti-Ro/SSA level and
specificity (52 or 60 kd).
Methods. We studied adult SLE patients from 19 centers participating in the Systemic Lupus International Collaborating
Clinics (SLICC) Inception Registry. Demographics, disease activity (Systemic Lupus Erythematosus Disease Activity Index
2000 [SLEDAI-2K]), disease damage (SLICC/American College of Rheumatology Damage Index [SDI]), and laboratory data
from the baseline or first followup visit were assessed. Multivariate logistic and linear regression models were used to
asses for any cross-sectional associations between anti-Ro/SSA and EKG repolarization abnormalities.
Results. For the 779 patients included, mean ! SD age was 35.2 ! 13.8 years, 88.4% were women, and mean ! SD disease
duration was 10.5 ! 14.5 months. Mean ! SD SLEDAI-2K score was 5.4 ! 5.6 and mean ! SD SDI score was 0.5 ! 1.0. EKG
abnormalities were frequent and included nonspecific ST-T changes (30.9%), possible left ventricular hypertrophy (5.4%),
and supraventricular arrhythmias (1.3%). A QTc >440 msec was found in 15.3%, while a QTc >460 msec was found in
5.3%. Mean ! SD QTd was 34.2 ! 14.7 msec and QTd >40 msec was frequent (38.1%). Neither the specificity nor the level
of anti-Ro/SSA was associated with QTc duration or QTd, although confidence intervals were wide. Total SDI was
significantly associated with a QTc interval exceeding 440 msec (odds ratio 1.38 [95% confidence interval 1.06, 1.79]).
Conclusion. A substantial proportion of patients with recent-onset SLE exhibited repolarization abnormalities, although
severe abnormalities were rare.
INTRODUCTION
Electrocardiography (EKG) is an inexpensive, universally
available noninvasive tool that has the potential to detect
important systemic lupus erythematosus (SLE)–associated
cardiovascular involvement, including rhythm distur-
bances and underlying repolarization abnormalities. Ab-
normal cardiac repolarization is generally assessed by the
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detection of prolongation of the heart rate corrected QT
(QTc) interval and increased QT dispersion (QTd), defined
as the difference between maximal and minimal QT
intervals from different EKG leads. Because these EKG
abnormalities may confer an increased risk of ventricular
arrhythmias and sudden cardiac death (1,2), early identi-
fication may have prognostic value.
Some evidence suggests that anti-Ro/SSA antibodies,
strongly associated with congenital heart block in neonatal
lupus, may also lead to QTc prolongation among adults
with systemic autoimmune rheumatic diseases (3,4). In
addition, the specific anti-Ro/SSA subtype (against 52-kd
or 60-kd subunit) as well as its level may be important
factors in determining the effect of this autoantibody on
the cardiomyocytes, both in the fetus and in adults (5,6).
Previous studies that attempted to examine the relation-
ship between anti-Ro/SSA antibodies and QTc prolonga-
tion in systemic autoimmune rheumatic diseases were sin-
gle center and limited by a relatively small number of
participants. Therefore, the literature is scant and conflict-
ing, and the effect of anti-Ro/SSA in adults with SLE
remains unclear (7,8).
Given this background, we evaluated the prevalence of
various EKG abnormalities in a large international incep-
tion cohort of patients with SLE and assessed for possible
associations between repolarization abnormalities (QTc
prolongation and increased QTd) and various clinical and
laboratory variables, including the anti-Ro/SSA level and
specificity (52 and 60 kd).
MATERIALS AND METHODS
Study population. The Systemic Lupus International
Collaborating Clinics (SLICC) is a group of SLE experts
who have developed an international registry of newly
diagnosed SLE patients, the SLICC Prospective Inception
Cohort. The present analysis includes adult patients from
19 centers in 8 different countries participating in this
inception cohort. Patients were enrolled within 15 months
of their date of diagnosis based on American College of
Rheumatology (ACR) classification criteria (9). Patients in
this registry are followed prospectively and undergo a
yearly research visit, where demographics, disease activity
(Systemic Lupus Erythematosus Disease Activity Index
2000 [SLEDAI-2K] [10]), disease damage (SLICC/ACR
Damage Index [SDI] [11]), clinical features of SLE, coro-
nary artery disease (CAD) risk factors, and laboratory data
are collected. Data from centers performing routine annual
Centre and Dalhousie University, Halifax, Nova Scotia, Can-
ada; 8Daniel J. Wallace, MD: Cedars-Sinai Medical Center,
Los Angeles, California; 9Caroline Gordon, MD, FRCP: Uni-
versity of Birmingham, Birmingham, UK; 10David Isenberg,
MD, Anisur Rahman, PhD, FRCP: University College Lon-
don, London, UK; 11Paul R. Fortin, MD, MPH, FRCPC: Cen-
tre Hospitalier Universitaire de Que´bec, Universite´ Laval,
Que´bec, Que´bec, Canada; 12Joan T. Merrill, MD: Oklahoma
Medical Research Foundation, Oklahoma City; 13Juanita
Romero-Diaz, MD, MS, Jorge Sanchez-Guerrero, MD, MS:
National Institute of Nutrition, Mexico City, Mexico; 14Barri
Fessler, MD, MSPH, Graciela S. Alarco´n, MD, MPH: Univer-
sity of Alabama at Birmingham; 15Kristja´n Steinsson, MD,
PhD: Landspitali University Hospital, Reykjavik, Iceland;
16Ian N. Bruce, MD, FRCP: NIHR Manchester Musculoskel-
etal Biomedical Research Unit, University of Manchester,
Manchester, UK; 17Ellen Ginzler, MD, MPH: State Uni-
versity of New York Health Science Centre, Brooklyn;
18Mary Anne Dooley, MSc: University of North Carolina,
Chapel Hill; 19Ola Nived, MD, PhD, Gunnar Sturfelt, MD,
PhD: University Hospital Lund, Lund, Sweden; 20Kenneth
Kalunian, MD: University of California, San Diego;
21Manuel Ramos-Casals, MD, PhD: Servicio de Enferme-
dades Autoinmunes, Barcelona, Spain; 22Michelle Petri,
MD, MPH: Johns Hopkins University, Baltimore, Maryland;
23Asad Zoma, FRCP: Stonehouse Hospital, Glasgow, UK.
Dr. Krantz has received consulting fees, speaking fees,
and/or honoraria (less than $10,000 each) from Reckitt/
Cardiocore and Abbott Vascular, and (more than $10,000)
from Novo Nordisk. Dr. Bruce has received consulting fees,
speaking fees, and/or honoraria (less than $10,000 each)
from GSK, MedImmune, Pfizer, Roche, and UCB. Dr. Nived
has received consulting fees, speaking fees, and/or hono-
raria (less than $10,000 each) from GSK and UCB. Dr.
Sturfelt has received speaking fees (less than $10,000) from
GSK.
Address correspondence to Christian A. Pineau, MD,
FRCPC, The Montreal General Hospital, 1650 Cedar Ave-
nue, A6.163, Montreal, Quebec H3G 1A4, Canada. E-mail:
Christian.pineau@mcgill.ca.
Submitted for publication January 20, 2014; accepted in
revised form May 6, 2014.
Significance & Innovations
● Electrocardiography (EKG) has the potential to de-
tect important systemic lupus erythematosus
(SLE)–associated cardiovascular involvement. Al-
though patients were young (mean age 35.2 years)
and had a short disease duration (mean 10.5
months), patients in the Systemic Lupus Interna-
tional Collaborating Clinics inception cohort
already demonstrated evidence of cardiac abnor-
malities by EKG, including repolarization ab-
normalities that confer an increased risk for ven-
tricular arrhythmias and sudden death.
● Although the pathogenic role of anti-Ro/SSA in
the fetal heart is well recognized, its effect on the
adult heart is uncertain, and previous studies that
attempted to examine the relationship between an-
ti-Ro/SSA antibodies and repolarization abnor-
malities in SLE patients were single center and
limited by a relatively small number of partici-
pants. We did not demonstrate an association
between repolarization abnormalities and the anti-
Ro/SSA specificities or level in our large popula-
tion of 779 SLE patients.
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12-lead resting EKGs have been used (19 from the 27
centers participating in this cohort in 2008). Participants
included in the present analysis had baseline research
visits between October 1999 and December 2008.
Study variables. Clinical and laboratory variables from
the baseline or the first followup visit were studied as
potential factors associated with EKG abnormalities, and
included age, sex, disease duration, SLEDAI-2K, SDI, ar-
terial hypertension (!140/90 mm Hg recorded at visit),
body mass index, current smoking status, alcohol con-
sumption, history of CAD (including myocardial infarc-
tion, percutaneous coronary intervention, and coronary
bypass surgery), valvular heart disease, and cardiomy-
opathy. Relevant medication use that could impact cardio-
vascular status included nonsteroidal antiinflammatory
drugs, antimalarials, antihypertensive agents (diuretics,
adrenergic inhibitors, beta-blockers, central alpha ago-
nists, calcium-channel blockers, angiotensin-converting
enzyme inhibitors, and angiotensin receptor blockers),
nitrates, lipid-lowering agents, steroids, warfarin, heparin,
acetylsalicylic acid, contraceptive pills, hormone re-
placement, thyroid replacement, and immunosuppressive
drugs, including azathioprine, mycophenolate mofetil,
methotrexate, and cyclophosphamide. The following lab-
oratory tests were performed in a central laboratory:
calcium, albumin, potassium, and magnesium levels; anti–
double-stranded DNA; and anti–extractable nuclear anti-
gen (anti-ENA) profile (anti-Ro/SSA subspecificities [52 kd
and 60 kd], anti-La/SSB, anti-Sm, and anti-RNP). The mea-
surement of autoantibodies was performed by addressable
laser bead immunoassay (BioPlex 2200; Bio-Rad), which
permits the simultaneous detection of all autoantibodies of
interest. Patients were classified as positive or negative
(cutoff value of !1.0 autoantibody index as positivity) and
the titer of the positivity was measured. Lipid profile (with
hyperlipidemia defined as greater than the upper limit of
the testing laboratory), glucose (with diabetes mellitus de-
fined as fasting blood glucose !7 mmoles/liter), and high-
sensitivity C-reactive protein level were measured at local
laboratories.
EKG. Depending on the quality of the printout, the 12-
lead EKG from either the baseline or the first followup visit
(25 mm/second paper speed and 10 mm/mV amplitude)
was initially manually interpreted by 3 board-certified car-
diologists blinded to any clinical information at an inde-
pendent central core laboratory. Rhythm, conduction dis-
eases, ST-T changes, chamber hypertrophy, QT interval
duration, and QTd were assessed. The QT intervals were
assessed without magnification and recorded in millisec-
onds approximated to the nearest 10 msec. The QT inter-
val was defined as the time between the first deflection
from the isoelectric PR interval and the visual return of the
T wave to the T-P segment. Measurements immediately
following atrial or ventricular premature contractions
were avoided. Computer-assisted reading was also per-
formed and interpretations were performed according to
International Conference on Harmonisation (ICH) guide-
lines (12). For those lacking computer-generated QTc, the
median raw QT was used to derive the Bazett QTc interval
(13). QTd was defined as the difference between maximal
and minimal QT intervals and required a minimum of 8
interpretable leads, as previously described (14). Propor-
tions of patients with QTc prolongation crossing categori-
cal regulatory thresholds according to the ICH guidance
document (440 msec, 450 msec, 460 msec, 480 msec, and
500 msec) (12) and increased QTd (defined as !40 msec)
were also assessed.
Statistical analyses. Descriptive statistics are shown us-
ing means, medians, SDs, interquartile ranges, and propor-
tions, as appropriate. We first estimated the effects of var-
ious demographic, clinical, and laboratory factors on the
prolongation of the QTc interval using univariate analyses.
We also fit multivariate logistic and linear models, which
included continuous variables for age, SLE disease dura-
tion, SLEDAI-2K, SDI, and corrected calcium, potassium,
and magnesium levels, as well as dichotomous variables
for sex, anti-ENA, CAD risk factors, and drug exposure. We
investigated confounding by comparing odds ratios (ORs)
for each main variable of interest as possible confounders
exited or entered the model. Analyses were performed
using SAS software, version 9.2. The study was approved
by the institutional ethics boards of the involved clinics
and written consent was obtained from each subject ac-
cording to the Declaration of Helsinki.
RESULTS
Characteristics of the patients. Seven hundred seventy-
nine subjects participated in this study. Baseline charac-
teristics of the patients are shown in Table 1. The majority
(88.4%) were women, 50.7% were white, 22.9% were
Asian, 13.1% were African American, and 9.3% were His-
panic. At assessment, the mean " SD age was 35.2 " 13.8
years and the mean " SD lupus disease duration was
short, at 10.5 " 14.5 months, as would be expected with an
inception cohort. At the time of the assessment, 47.3% had
positive anti-Ro/SSA (52 and/or 60 kd), among which
30.2% were anti-Ro/SSA 52 kd positive, 44.2% were anti-
Ro/SSA 60 kd positive, and 27.0% were both anti-Ro/SSA
52 and 60 kd positive. Cardiovascular history and risk
factors among the study participants are detailed in
Table 2. Thirty-one percent of the patients had hyperten-
sion and 14.8% were current smokers. Known CAD and
structural heart disease were relatively uncommon in the
cohort.
EKG abnormalities. The proportions of patients with
various EKG abnormalities are shown in Table 3. Prema-
ture atrial and ventricular complexes occurred in 1.15%
and 1.40% of the patients, respectively. Atrial fibrillation
and other supraventricular arrhythmias were less frequent
(0.13%). Prominent QRS voltages, suggestive of left ven-
tricular hypertrophy, were found in 5.40% of this popula-
tion of young patients. Among the patients with ventricu-
lar conduction disturbances, incomplete bundle branch
block was the most frequent abnormality. Nonspecific
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ST-T segment occurred in 30.9%. A high prevalence of
repolarization abnormalities was found in our population,
with 15.3% having prolonged QTc (!440 msec) and
38.1% having increased QTd.
Clinical and laboratory associations. Table 4 compares
the rate of repolarization abnormalities among the various
Ro/SSA subgroups (Ro/SSA negative, Ro/SSA 52 kd pos-
itive, Ro/SSA 60 kd positive, Ro/SSA 52 kd and/or 60 kd
positive, and both Ro/SSA 52 kd and 60 kd positive).
Although the mean QTc and the proportion of patients
with QTc !440 msec were slightly higher in Ro/SSA-
positive groups compared to the Ro/SSA-negative group,
wide confidence intervals (CIs) preclude definitive conclu-
sions.
In univariate and multivariate analyses, anti-Ro/SSA
antibodies, for any subtype, were not associated with QTc
prolongation (Table 5) or increase in QTd (Table 6). Sim-
ilarly, there was no effect of anti-Ro/SSA level on these
parameters (data not shown).
Other variables. In univariate analysis, the following
variables were associated with QTc prolongation and
showed a stronger association for higher QTc cut points:
antihypertensive drug (ORs 2.10 [95% CI 1.34, 3.29] to
7.22 [95% CI 1.44, 36.11]) and age (ORs 1.02 [95% CI 1.01,
1.04] to 1.07 [95% CI 1.02, 1.12]), depending on the QTc
thresholds. Because of the small numbers, we were unable
to demonstrate if any specific antihypertensive medication
Table 1. Characteristics of the patients*
Value
(n " 779)
Age, mean " SD years 35.2 " 13.8
Female sex 88.4
Ethnicity
White 50.7
Asian 22.9
African American 13.1
Hispanic 9.3
Other 4.0
Disease duration, mean " SD months 10.5 " 14.5
SLEDAI-2K score, mean " SD 5.4 " 5.6
Current nephrotic syndrome 5.2
Active nephritis 18.7
Current hemodialysis 0.7
SDI score, mean " SD 0.5 " 1.0
Antibodies
Anti-Ro/SSA (52 kd and/or 60 kd) 47.3
Anti-La/SSB 20.2
Anti-Sm 30.6
Anti-RNP 12.4
Anti-DNA 43.9
Medications, current use†
NSAIDs 20.8
Antimalarials 68.4
Immunosuppressants 38.1
Steroids 66.7
Aspirin 16.2
Anticoagulants 5.5
Antihypertensives 31.0
Oral contraceptives 11.1
Hormone therapy 3.6
Low potassium level‡ 10.9
Low magnesium level§ 15.2
Low calcium level¶ 13.3
* Values are the percentage unless indicated otherwise. SLEDAI-
2K # Systemic Lupus Erythematosus Disease Activity Index
2000; SDI # Systemic Lupus International Collaborating Clinics/
American College of Rheumatology Damage Index; NSAIDs # non-
steroidal antiinflammatory drugs.
† No patients were using antipsychotics, human immunodeficiency
virus protease inhibitors, or cocaine.
‡ Defined as "3.4 mmoles/liter.
§ Defined as "0.74 mmoles/liter.
¶ Defined as "2.10 mmoles/liter.
Table 2. Cardiovascular status among study participants
Study
participants
(n " 779)
Current smokers, no. (%) 115 (14.8)
Alcohol consumption, mean " SD
per week
1.0 " 3.3
Body mass index, mean " SD kg/m2 25.1 " 6.3
Hypertension, no. (%)* 212 (31.0)
Diabetes mellitus, no. (%) 20 (2.6)
High-sensitivity C-reactive protein,
mean " SD
4.9 " 13.8
* Data on the total population were not available and the denomi-
nator is slightly less than 779.
Table 3. Electrocardiographic abnormalities*
Value
(n " 779)
Supraventricular arrhythmias
Premature atrial complexes 1.15
Atrial fibrillation 0.13
Atrial flutter/supraventricular
tachycardia/wandering pacemaker
0
Premature ventricular contractions 1.40
Atrioventricular heart block 0.64
Left ventricular hypertrophy 5.4
Right ventricular hypertrophy 0.1
Ventricular conduction disturbances
Incomplete bundle branch block 2.68
Right bundle branch block 0.77
Left bundle branch block 0.26
Left anterior fascicular block 0.38
Left posterior fascicular block 0
ST segment changes
Nonspecific 30.9
Compatible with myocardial infarction 1.83
QTc, mean " SD msec 415.3 " 25.7
Increased QTc (!440 msec) 15.3
Increased QTc (!460 msec) 5.3
QTd, mean " SD msec 34.2 " 14.7
Increased QTd (!40 msec) 38.1
* Values are the percentage unless indicated otherwise. All atrio-
ventricular heart blocks were first-degree blocks. QTc # corrected
QT interval; QTd # QT dispersion.
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was associated with increased QTc intervals. Some vari-
ables showed an association only at certain QTc cut
points: thyroid replacement therapy (OR 2.45 [95% CI
1.38, 4.36]) at a cutoff of !440 msec and total SDI (OR 1.38
[95% CI 1.06, 1.79] at !440 msec and OR 1.39 [95% CI
1.03, 1.87] at !450 msec).
Contribution of the variables to multivariate models has
been assessed and, with the exception of antihypertensive
drugs and increasing age, we were unable to determine if
any clinical or laboratory factors were associated with
prolonged QTc or QTd (Table 5). In particular, although
the CIs were large, neither the level of electrolytes (potas-
sium, magnesium, or corrected calcium) nor the presence
of any antibodies was found to impact QTc interval dura-
tion or QTd.
DISCUSSION
Our study is by far the largest to date evaluating EKG
abnormalities and more specifically, the relationship be-
tween anti-Ro/SSA and repolarization abnormalities in
SLE patients. Although many patients in our cohort were
young (mean age 35.2 years) and had a short disease du-
ration (mean 10.5 months), a considerable number of pa-
tients in the SLICC cohort already demonstrated evidence
of cardiac abnormalities by EKG. In data from a healthy
population of women ages 25–44 years (15), the mean
prevalence of most EKG abnormalities has been reported
to be relatively low: 0.1% atrioventricular block, 0.2%
bundle branch block, 0.04% atrial fibrillation or flutter,
and 0.1% QRS voltage criteria indicative of left ventricular
hypertrophy. However, our cohort was not restricted to
women and also included subjects older than the age range
25–44 years. However, analyzing the sample of women
ages 25–44 years from our cohort, the mean prevalence of
most EKG abnormalities remains high, at 0.85% atrioven-
tricular block, 4.79% bundle branch block, and 4.2% left
ventricular hypertrophy, although atrial fibrillation or flut-
ter was not seen in this subpopulation. Abnormalities such
as conduction defects may represent sequelae of past or
active lupus myocarditis (16) and could also be related to
the high rate of CAD risk factors such as hypertension in
our patients, although SLE itself carries an independent
risk for CAD even after adjustment for traditional Framing-
ham risk factors (17).
Although a substantial proportion of patients in our
cohort manifested repolarization abnormalities such as
prolonged QTc (15.3%) and increased QTd (38.1%), se-
Table 5. Multivariate analyses for QTc as a continuous variable and for different QTc thresholds*
QTc QTc >440 msec QTc >450 msec QTc >460 msec QTc >480 msec
Age 0.33 (0.17, 0.49)† 1.01 (0.99, 1.03) 1.03 (1.01, 1.05)† 1.04 (1.01, 1.06)† 1.07 (1.02, 1.12)†
Antihypertensive 5.93 (1.20, 10.70)† 1.90 (1.57, 3.11)† 2.62 (1.43, 4.80)† 3.26 (1.49, 7.15)† 5.91 (1.15, 30.16)†
Ro/SSA 52 kd positive 3.33 ($1.35, 8.00) 1.45 (0.88, 2.41) 1.60 (0.85, 3.00) 0.95 (0.43, 2.10) 0.93 (0.18, 4.84)
Ro/SSA 60 kd positive 1.47 ($2.66, 5.6) 1.36 (0.86, 2.30) 1.25 (0.71, 2.20) 0.48 (0.21, 1.13) 0.50 (0.10, 2.62)
Ro/SSA 52 kd and/or 60 kd
positive
2.25 ($1.87, 6.34) 1.32 (0.81, 2.12) 1.51 (0.86, 2.67) 0.64 (0.28, 1.43) 0.44 (0.09, 2.30)
Ro/SSA 52 kd and 60 kd
positive
2.72 ($2.08, 7.53) 1.37 (0.82, 2.30) 1.32 (0.72, 2.42) 0.64 (0.26, 1.59) 1.09 (0.21, 5.67)
* Values are the odds ratio (95% confidence interval) from multivariate analysis, except for the first column, where they are the regression coefficient
(95% confidence interval) from linear regression models. Variables not appearing in the table were removed from the final model because they were
not predictive of the outcome nor they were confounders. The small number of patients (n # 2) with QTc !500 msec precludes multivariate analysis
at this threshold. QTc # corrected QT interval.
† Significant.
Table 4. QT characteristics among systemic lupus erythematosus patients with various Ro/SSA positivity statuses*
Ro/SSA
negative
(n " 314)
Ro/SSA 52 kd
positive
(n " 180)
Ro/SSA 60 kd
positive
(n " 264)
Ro/SSA 52 kd
and/or 60 kd
positive
(n " 283)
Ro/SSA 52 kd
and Ro 60 kd
positive
(n " 161)
QTc, mean " SD msec 413.5 " 26.5 416.7 " 24.9 415.5 " 24.4 415.9 " 24.6 416.2 " 24.6
QTc minimum, msec 343 352 352 352 352
QTc maximum, msec 562 488 488 488 488
Increased QTc, % !440 msec 12.4 17.8 16.7 17.0 17.4
Increased QTc, % !460 msec 5.7 5 3.8 4.6 3.7
QTd, mean " SD msec 32.4 " 14.8 33.2 " 16.2 33.9 " 16.1 34.1 " 16.3 32.8 " 15.8
Increased QTd, % !40 msec 37.6 38.2 40.8 40.9 37.7
* Complete anti-Ro/SSA serologies (52 and 60 kd) were available for 597 patients. QTc # corrected QT interval; QTd # QT dispersion.
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vere abnormalities were rare (%1% with QTc !550 msec).
QTc prolongation is an independent risk factor for the
development of complex ventricular arrhythmias, and
rarely, sudden death (1,2). Increased QTd is another indi-
cator of myocardial electrical instability that has been
associated with arrhythmias and cardiac death (18). In
general medical populations, QTd is an independent pre-
dictor of cardiovascular mortality (hazard ratio 1.28 [95%
CI 1.01, 1.60] per each 10-msec increase in QTd) (19). In
patients with rheumatic diseases, a 50-msec increase in
the QTc interval has been associated with a doubling of the
relative hazard for all-cause mortality, and some authors
have suggested a connection between disease activity and
arrhythmogenesis (20). Important associations of repolar-
ization abnormalities in our study included age and anti-
hypertensive therapy, which is not surprising, since both
have been associated with prolonged QTc (21–23). Wide
CIs precluded definitive conclusions for other clinical and
laboratory variables in our study, although numerical in-
creases in the QTc interval were observed with anti-Ro/
SSA antibody positivity.
Because of their recognized arrhythmogenic effect on
the fetal heart, anti-Ro/SSA antibodies have been exam-
ined as potential determinants of QTc prolongation in
adults with connective tissue diseases (CTDs). The patho-
genic role of anti-Ro/SSA and anti-La/SSB antibodies in
neonatal lupus is universally accepted, although the exact
mechanisms of injury have not been completely clarified.
In vivo and in vitro evidence supports a pathologic cas-
cade involving cardiomyocytes apoptosis, binding of ma-
ternal antibodies, inflammation, and subsequent replace-
ment of inflamed tissue with fibrosis (24–27). Inhibition of
L-type and T-type calcium channels also seems to play an
important role (28). However, these mechanisms, which
generally lead to irreversible conduction abnormalities,
would not explain the reversible changes that are hypoth-
esized to occur in adult patients. Indeed, some evidence,
such as the concomitant disappearance of QTc abnormal-
ities and acquired maternal autoantibodies during the first
year of life (29), suggests that anti-Ro/SSA antibodies may
cause a direct reversible arrythmogenic effect on ventric-
ular repolarization. However, the pathophysiology under-
lying QTc prolongation seems to be different from the one
involved in neonatal cardiac block, and evidence suggests
an inhibitory activity of these autoantibodies on the potas-
sium currents, resulting in an impairment of the ventric-
ular repolarization (30).
In patients with various types of CTD, Lazzerini and
colleagues showed statistically significant prolongation of
the QTc interval in anti-Ro/SSA–positive adults compared
to anti-Ro/SSA–negative adults (4,5,31). Our previous
single-center study, performed on a large group of SLE
patients with a mean age of 44.8 years and a mean disease
duration of 12.9 years, also demonstrated an association
between anti-Ro/SSA antibodies and QTc interval prolon-
gation (3). In the current study, although the proportion of
patients with prolonged QTc was slightly higher in anti-
Ro/SSA–positive groups compared to the anti-Ro/SSA–
negative group, CIs were wide and included both impor-
tant effects and the null value, and therefore were
inconclusive. In contrast to a recent study reporting that
QTc prolongation was strictly dependent on the anti-
Ro/SSA 52-kd level in a population of 49 subjects with
various CTDs (5), we did not demonstrate an association
between the anti-Ro/SSA specificities or level in our pop-
ulation of 779 SLE patients. Our results are, however, in
accordance with previous studies involving a majority of
SLE patients who did not demonstrate differences in QTc
duration or QTd between anti-Ro/SSA–positive and anti-
Ro/SSA–negative patients (7,8,32). It has been proposed
previously that SLE patients may have a peculiar resis-
tance to the hypothesized electrophysiologic effects of
anti-Ro/SSA antibodies as compared with patients with
other CTDs (33). It may also be possible that our lack of
ability to show an effect was because of the young age and
short disease duration of the patients in our cohort.
Numerous centers around the world participated in our
study, and some factors that may impact EKG acquisition
(e.g., type of EKG equipment, body position, and fasting
state of the participants) were not standardized. However,
both EKG interpretation and antibody testing were per-
formed with highly robust methods in a single center.
Because no association was found between antiphospho-
lipid antibodies and EKG abnormalities in previous stud-
ies, we did not test for these autoantibodies (3). Other
potential limitations of the present study include the use
of resting 12-lead EKGs rather than 24-hour EKG monitor-
ing (Holter), which can measure diurnal variations of EKG
intervals. However, it has been previously shown that QTc
prolongation, when present, persists for most of the 24-
hour observation period (31). For those lacking computer-
generated QTc (21.8% of the participants), the median raw
QT was used to derive the Bazett QTc interval, which
overcorrects at high heart rates and undercorrects at low
heart rates (13). This could contribute to the null effect of
our study. Since the threshold at which QTc duration
should be considered abnormal also has been a matter of
Table 6. Multivariate analyses for QTd*
QTd QTd >40 msec
Age 0.09 ($0.01, 0.18) 1.01 (0.99, 1.02)
Ro/SSA 52 kd
positive
$0.01 ($2.78, 2.76) 0.94 (0.65, 1.35)
Ro/SSA 60 kd
positive
1.30 ($1.26, 3.86) 1.13 (0.80, 1.58)
Ro/SSA 52 kd
and/or 60 kd
positive
1.68 ($0.86, 4.22) 1.14 (0.82, 1.6)
Ro/SSA 52 kd
and 60 kd
positive
$0.54 ($3.41, 2.32) 0.92 (0.63, 1.34)
* Values are the regression coefficient (95% confidence interval)
from linear regression models for QTd and the odds ratio (95%
confidence interval) from logistic regression models for QTd !40
msec. Variables not shown in the table were removed from the final
model because they were not predictive of the outcome nor they
were confounders. QTd # QT dispersion.
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debate for many years (34,35), we used different cutoffs in
our analysis, from 440 msec to 500 msec.
In conclusion, we demonstrated a relatively high prev-
alence of EKG abnormalities, including repolarization ab-
normalities, in this inception cohort, although severe ab-
normalities were rare.
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Erratum
In the article by Humphreys et al in the September 2014 issue of Arthritis Care & Research (pages 1296–1301)
an error was detected in the Results. On page 1298, the sentence beginning “Overall, persistently increasing,
but stable mortality rates . . . ” should have read “Overall, persistently increased, but stable mortality rates
over time were seen in patients with RA, when modeled by calendar year.”
We regret the error.
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